Laponis Adam 4
4 · Twist Bioscience Corp · Filed Apr 21, 2026
Research Summary
AI-generated summary of this filing
Twist Bioscience CFO Adam Laponis Sells 4,000 Shares
What Happened
Adam Laponis, Chief Financial Officer of Twist Bioscience (TWST), sold 4,000 shares on April 17, 2026 at $60.00 per share, generating proceeds of $240,000. This was a sale (not a purchase or option exercise) and was executed pursuant to a previously adopted trading plan.
Key Details
- Transaction date: 2026-04-17; Filing date (Form 4): 2026-04-21 (filed within the SEC’s 2 business-day window).
- Transaction type/code: Sale (S) — open market or private sale reported.
- Shares sold: 4,000 at $60.00 each; total reported proceeds $240,000.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnote: Sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025 (pre-established plan).
Context
Sales by executives are common and often routine; a 10b5-1 plan indicates this sale was pre-arranged and should not be taken alone as a signal of changed company outlook. Purchases generally carry more weight for interpreting insider sentiment.
Insider Transaction Report
Form 4
Laponis Adam
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1]2026-04-17$60.00/sh−4,000$240,000→ 118,694 total
Footnotes (1)
- [F1]The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025.
Signature
/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis|2026-04-21